Annonce • 2h
Zydus Worldwide DMCC completed the acquisition of Assertio Holdings, Inc. (NasdaqCM:ASRT). Zydus Worldwide DMCC entered into definitive agreement to acquire Assertio Holdings, Inc. (NasdaqCM:ASRT) for approximately $160 million on May 13, 2026. A cash consideration valued at $23.5 per share and will be paid by Zydus Worldwide DMCC. Zydus will acquire any remaining shares through a second-step merger at the same price of $23.50 per share in cash. In case of termination of transaction, seller will pay a termination fee of $6.26 million.
The transaction is subject to minimum tender and minimum balance sheet requirements. The deal has been unanimously approved by the board of Assertio Holdings, Inc. The Board determined that the Zydus Offer constituted a “Superior Proposal” under the Garda Merger Agreement and authorized the Company to terminate the Garda agreement announced on May 4, 2026. The Zydus Transaction is expected to close in the second quarter of 2026. The transaction is expected to close on June 16, 2026.
Moelis & Company LLC acted as financial advisor for Assertio Holdings, Inc. Moelis & Company LLC acted as fairness opinion provider for Assertio Holdings, Inc. Chelsea Darnell and Krishna Veeraraghavan of Paul, Weiss, Rifkind, Wharton & Garrison LLP acted as legal advisor to Zydus Worldwide DMCC. Ryan Murr, Branden Berns and Evan D’Amico of Gibson, Dunn & Crutcher LLP acted as legal advisor to Assertio Holdings, Inc. Longacre Square Partners as strategy and communications advisor for Assertio Holdings, Inc. Innisfree M&A Incorporated acted as information agent for Zydus Worldwide DMCC. Equiniti Trust Company acted as transfer agent for Assertio Holdings, Inc.
Zydus Worldwide DMCC completed the acquisition of Assertio Holdings, Inc. (NasdaqCM:ASRT) on June 16, 2026. The Company and Purchaser completed the cash offer at a purchase price of $23.50 per share of common stock of Assertio, without interest, less deduction for any required withholding taxes. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on June 15, 2026, 4,286,488 shares of common stock were validly tendered and not withdrawn, representing approximately 66.32% of the total number of Assertio’s issued and outstanding shares of common stock. All such shares have been accepted for payment in accordance with the terms of the tender offer, and the Company expects to promptly pay for such shares. Assertio will continue to operate as a wholly-owned subsidiary of Zydus Lifesciences. Effective today, Assertio common stock has been delisted from the Nasdaq Stock Exchange. Annonce • May 15
Assertio Holdings Inc.'s Common Stock to Be Delisted from Nasdaq Zydus Lifesciences has agreed to acquire all outstanding common shares of Assertio Holdings, Inc. in an all-cash transaction valued at approximately USD 166.4 million. The acquisition will be carried out through Zydus Worldwide DMCC, a subsidiary of Zydus, and marks another major step in the company’s efforts to strengthen its specialty pharmaceutical business in the United States. Under the agreement, Zydus will acquire Assertio shares at USD 23.50 per share in cash. The offer represents a 30.6% premium over Garda Therapeutics’ earlier USD 18.00 per share bid announced on April 8, 2026 and a 7.8% premium over Garda’s revised USD 21.80 per share offer made on May 4, 2026. The board carefully assessed the transaction’s value, execution certainty, and overall terms before concluding that the Zydus offer represented the best available option for shareholders. Zydus will shortly begin a tender offer to acquire all outstanding Assertio shares. The transaction is expected to close during the second quarter of 2026, subject to customary closing conditions, including the tender of a majority of Assertio’s shares. Once the tender process concludes, Zydus plans to acquire any remaining shares through a second-step merger at the same price of USD 23.50 per share. Following completion, Assertio’s common stock will be delisted from Nasdaq. Annonce • Apr 10
Assertio’s Common Stock to No Longer Be Listed for Trading on Nasdaq, Following the Completion of the Tender Offer Assertio Holdings, Inc. (“Assertio” or the “Company”) announced a definitive agreement (the “Garda Agreement”) to be acquired by Garda Therapeutics (“Garda” or the “Buyer”) for $18 per share in cash, or a total cash consideration of $125.1 million, plus a contingent value right (the “CVR”). The Garda Transaction has been unanimously approved by the Boards of Directors of both companies. Under the terms of the Garda Agreement, Garda will promptly commence a tender offer to acquire all outstanding shares of Assertio Holdings at an upfront price of $18 per share in cash, or a total cash consideration of $125.1 million, plus a non-tradeable CVR related to potential future milestones for Sprix®. The Company’s Board of Directors unanimously recommends that Assertio stockholders tender their shares in the tender offer. The closing of the Garda Transaction is expected to occur in the Second Quarter of 2026 and is subject to customary closing conditions, including the tender of a majority of the outstanding shares of Assertio’s common stock. The Company does not expect any regulatory approvals to be required for closing. Following the successful closing of the tender offer, Garda will acquire all remaining shares of Assertio Holdings’ common stock that are not tendered in the tender offer through a second-step merger at the same price as the tender offer of $18 per share, plus the CVR. Following the completion of the tender offer, Assertio’s common stock will no longer be listed for trading on Nasdaq. Price Target Changed • Apr 09
Price target decreased by 27% to US$27.25 Down from US$37.44, the current price target is an average from 4 analysts. New target price is 51% above last closing price of US$18.02. The company is forecast to post a net loss per share of US$0.17 next year compared to a net loss per share of US$4.74 last year. Annonce • Apr 09
Garda Therapeutics entered into a definitive agreement to acquire Assertio Holdings, Inc. (NasdaqCM:ASRT) for approximately $140 million. Garda Therapeutics entered into a definitive agreement to acquire Assertio Holdings, Inc. (NasdaqCM:ASRT) for approximately $140 million on April 8, 2026. Under the terms of the agreement, Garda will promptly commence a tender offer to acquire all outstanding shares of Assertio Holdings at an upfront price of $18 per share in cash, or a total cash consideration of $125.1 million, plus a non-tradeable CVR related to potential future milestones for Sprix®. In a separate transaction, Assertio signed and closed an agreement to sell all non-Rolvedon assets to Cosette Pharmaceuticals. Colbeck Capital Management, LLC has committed to provide a senior secured term loan facility in an aggregate principal amount of $62 million and a senior secured delayed draw term loan facility in an aggregate principal amount of $25 million for the transaction. Following the completion of the tender offer, Assertio’s common stock will no longer be listed for trading on Nasdaq. In case of termination of transaction, Garda Therapeutics will pay a termination fee of $4.80 million and seller will pay a termination fee of $4.80 million. In the event the board terminates the agreement in favor of a superior bid during the window-shop period, a reduced breakup fee of $1.75 million would apply.
The transaction is subject to subject to customary closing conditions, including the tender of a majority of the outstanding shares of Assertio’s common stock and Assertio having a closing net cash of at least $115 million. The transaction has been unanimously approved by the Boards of Directors of both companies. The expected completion of the transaction is in the second quarter of 2026.
Moelis & Company LLC acted as financial advisor for Assertio Holdings, Inc. Ryan Murr, Branden Berns, and Evan D’Amico of Gibson, Dunn & Crutcher LLP acted as legal advisor for Assertio Holdings, Inc. Brett Lund of Paul Hastings LLP acted as legal advisor for Garda Therapeutics, Inc. Annonce • Apr 07
Assertio Holdings, Inc., Annual General Meeting, May 05, 2026 Assertio Holdings, Inc., Annual General Meeting, May 05, 2026. Reported Earnings • Mar 18
Full year 2025 earnings: EPS and revenues exceed analyst expectations Full year 2025 results: US$4.74 loss per share (further deteriorated from US$3.40 loss in FY 2024). Revenue: US$118.7m (down 5.0% from FY 2024). Net loss: US$30.4m (loss widened 41% from FY 2024). Revenue exceeded analyst estimates by 6.6%. Earnings per share (EPS) also surpassed analyst estimates by 21%. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 46% per year, which means it is performing significantly worse than earnings. Annonce • Mar 17
Assertio Holdings, Inc. Provides Earnings Guidance for the Full Year 2026 Assertio Holdings, Inc. provided earnings guidance for the full year 2026. For the year, the company expected net product sales (GAAP) of $110.0 million to $125.0 million. Annonce • Mar 04
Assertio Holdings, Inc. to Report Q4, 2025 Results on Mar 16, 2026 Assertio Holdings, Inc. announced that they will report Q4, 2025 results After-Market on Mar 16, 2026 Annonce • Jan 10
Assertio Holdings, Inc. Announces Publication of Rolvedon Same-Day Dosing Clinical Trial Assertio Holdings, Inc. announced that results of a clinical trial investigating a novel dosing schedule of Rolvedon®? (eflapegrastim-xnst) injection have been peer reviewed and published in The Oncologist. In the study of patients with early-stage breast cancer (ESBC), Rolvedon, when administered on the same day (same-day dosing) as TC chemotherapy (Taxotere (docetaxel) and cyclophosphamide) demonstrated an effective neutrophil recovery and an adverse event profile similar to that seen with next-day dosing. The Oncologist is the official peer-reviewed medical journal for the Society for Translational Oncology. Results of this study were first presented in December 2024 as part of the San Antonio Breast Cancer Symposium. This phase 1, multicenter (13 sites in the U.S.), open-label trial (NCT04187898) evaluated the efficacy and safety of Rolvedon administered on the same day as TC chemotherapy in patients (n = 53) with ESBC. A total of 53 patients enrolled; 49 completed the study. Patients received the recommended 13.2 mg (3.6 mg GCSF) fixed-dose of Rolvedon 30 min following TC chemotherapy. The benefits of eflapegrastim-xNst given same day as TC have not been evaluated in a randomized controlled trial. Annonce • Nov 22
Assertio Holdings, Inc. Announces Resignation of Brendan P. O’Grady from Board of Directors, Effective November 17, 2025 Assertio Holdings, Inc. announced that on November 17, 2025, Brendan P. O’Grady, former Chief Executive Officer of Assertio Holdings, Inc., executed a waiver and release agreement substantially in the form included with the Management Continuity Agreement between Mr. O’Grady and the Company, a form of which was filed as Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q filed on August 7, 2024. Pursuant to and in connection with his execution of the Waiver and Release Agreement, Mr. O’Grady resigned as a member of the Board of Directors of the Company, effective as of the effective date of the Waiver and Release Agreement. Major Estimate Revision • Nov 16
Consensus EPS estimates upgraded to US$0.40 loss The consensus outlook for fiscal year 2025 has been updated. 2025 losses forecast to reduce from -US$0.462 to -US$0.40 per share. Revenue forecast steady at US$111.4m. Pharmaceuticals industry in the US expected to see average net income decline 1.2% next year. Consensus price target broadly unchanged at US$2.66. Share price rose 4.0% to US$0.79 over the past week. Board Change • Nov 12
High number of new directors There are 5 new directors who have joined the board in the last 3 years. CEO & Director Mark L. Reisenauer was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annonce • Sep 15
Assertio Holdings, Inc. Presents First-Ever Real-World Study Showing Patient Experience with Sympazan (Clobazam) Oral Film, CIV Assertio Holdings, Inc. announced new data from a first-ever real-world study of SYMPAZAN (clobazam) Oral Film. The data were presented at the 150th Annual Meeting of the American Neurological Association (ANA2025) as a poster titled "M266: Real-World Evidence Study of Patients with Lennox-Gastaut Syndrome Taking Clobazam oral soluble film. Overall, 181 patients with epilepsy and a subset of 29 patients with LGS were identified. Sympazan (clobazam) oral film is approved only for the adjunctive treatment of seizures associated with LGS in patients two years of age and older. Study authors conducted a retrospective, new user cohort study using electronic health records collected during routine care at Stanford Health Care between 2015 and 2024. Patients were identified based on diagnoses for epilepsy or LGS, with information from health records of patients taking clobazam oral soluble film, including patient demographics, antiseizure medication use, and comorbidities. Managing LGS is challenging due to its treatment-resistant seizures and the need for individualized approaches to address evolving symptoms over a patient's lifetime. Major Estimate Revision • Aug 18
Consensus EPS estimates fall by 30% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$114.0m to US$111.8m. Losses expected to increase from US$0.35 per share to US$0.46. Pharmaceuticals industry in the US expected to see average net income growth of 0.01% next year. Consensus price target down from US$2.75 to US$2.63. Share price rose 12% to US$0.81 over the past week. Reported Earnings • Aug 13
Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2025 results: US$0.17 loss per share (further deteriorated from US$0.039 loss in 2Q 2024). Revenue: US$29.2m (down 6.1% from 2Q 2024). Net loss: US$16.4m (loss widened 345% from 2Q 2024). Revenue exceeded analyst estimates by 4.5%. Earnings per share (EPS) missed analyst estimates by 89%. Revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings. Price Target Changed • Aug 13
Price target decreased by 7.9% to US$2.63 Down from US$2.85, the current price target is an average from 4 analysts. New target price is 223% above last closing price of US$0.81. Stock is down 24% over the past year. The company is forecast to post a net loss per share of US$0.46 next year compared to a net loss per share of US$0.23 last year. Annonce • Aug 12
Assertio Holdings, Inc. Updates Earnings Guidance for the Full Year 2025 Assertio Holdings, Inc. updated earnings guidance for the full year 2025. For the year, the company now expects Net Product Sales (GAAP) of $108.0 Million to $118.0 Million against $108.0 million to $123.0 million as previously forecasted. Annonce • Aug 05
Assertio Holdings, Inc. to Report Q2, 2025 Results on Aug 11, 2025 Assertio Holdings, Inc. announced that they will report Q2, 2025 results After-Market on Aug 11, 2025 Reported Earnings • May 14
First quarter 2025 earnings: EPS and revenues miss analyst expectations First quarter 2025 results: US$0.14 loss per share (further deteriorated from US$0.047 loss in 1Q 2024). Revenue: US$26.5m (down 18% from 1Q 2024). Net loss: US$13.5m (loss widened 200% from 1Q 2024). Revenue missed analyst estimates by 3.7%. Earnings per share (EPS) also missed analyst estimates by 133%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 41% per year, which means it has not declined as severely as earnings. Price Target Changed • May 13
Price target decreased by 7.6% to US$2.80 Down from US$3.03, the current price target is an average from 5 analysts. New target price is 360% above last closing price of US$0.61. Stock is down 40% over the past year. The company is forecast to post a net loss per share of US$0.29 next year compared to a net loss per share of US$0.23 last year. Annonce • May 05
Assertio Holdings, Inc. to Report Q1, 2025 Results on May 12, 2025 Assertio Holdings, Inc. announced that they will report Q1, 2025 results After-Market on May 12, 2025 Annonce • Mar 26
Assertio Holdings, Inc., Annual General Meeting, May 07, 2025 Assertio Holdings, Inc., Annual General Meeting, May 07, 2025. Major Estimate Revision • Mar 19
Consensus EPS estimates fall by 154% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from US$123.7m to US$115.3m. Losses expected to increase from US$0.07 per share to US$0.18. Pharmaceuticals industry in the US expected to see average net income decline 1.3% next year. Consensus price target of US$2.85 unchanged from last update. Share price fell 8.8% to US$0.71 over the past week. Annonce • Mar 06
Assertio Holdings, Inc. to Report Q4, 2024 Results on Mar 12, 2025 Assertio Holdings, Inc. announced that they will report Q4, 2024 results After-Market on Mar 12, 2025 Board Change • Jan 02
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Mark Reisenauer was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Annonce • Dec 18
Assertio Holdings, Inc. Appoints Mark Reisenauer as Independent Director Assertio Holdings, Inc. announced that Mark Reisenauer has been appointed as an independent director to the Company's Board of Directors. Mr. Reisenauer will serve as a member of the Compensation Committee. Mark is a highly accomplished commercial leader in complex, competitive therapeutic areas who also brings extensive oncology and hematology product experience to their board, said Heather Mason, Chair of Assertio. His successful new product and indication launches have been grounded in an inclusive leadership style driven by communication, analysis, and partnership, all traits that are central to their strategy as they seek to build Assertios commercial platform. Mr. Reisenauer is an accomplished oncology and hematology biopharmaceutical executive with more than 30 years of experience building commercial capabilities and leading successful new product and indication launches. He previously served as President of U.S. Commercial at Astellas Pharmaceuticals Inc., where he grew sales to nearly $5 billion while leading Marketing, Sales, Policy and Government Affairs and Market Access teams. Prior to Astellas, he was Senior Vice President and Chief Commercial Officer at Micromet, Inc., which was acquired by Amgen, where he oversaw commercial launch and pipeline development activities. He was also at Abbott Laboratories, serving as a divisional vice president for neuroscience and general manager in oncology products. Earlier in his career, Mr. Reisenauer held roles at Pharmacia Corporation, Bristol-Myers Squibb and Zeneca Pharmaceuticals. He holds a Bachelor of Arts degree in political science from the University of Wisconsin. Annonce • Dec 13
Assertio Announces Results of Rolvedon (Eflapegrastim-Xnst) Injection Same-Day Dosing Clinical Study Assertio Holdings, Inc. announced results of a clinical trial investigating the utility of Rolvedon®? (eflapegrastim-xnst) injection when dosed the same day of chemotherapy for patients with early stage breast cancer (ESBC). The results were presented as part of the San Antonio Breast Cancer Symposium by the American Association of Cancer Research and the University of Texas Health Science Center at San Antonio. In this open-label, single-arm study (NCT04187898), conducted across 13 sites in the US, individuals received Rolvedon 30 minutes post chemotherapy for ESBC. Rolvedon demonstrated 1.8 days to neutrophil count recovery and a febrile neutropenia rate of 2%. Zero patients required the need for hospitalization and/or intervention for febrile neutropania. Annonce • Dec 12
Assertio Holdings, Inc. Announces Executive Changes Assertio Holdings, Inc. announced the creation of a new Transformation Office and the appointment of Paul Schwichtenberg as Chief Transformation Officer (CTO). Mr. Schwichtenberg currently serves as the company’s Chief Commercial Officer and was previously CFO. In addition, Mary Pietryga will be appointed as Chief Commercial Officer, effective December 16, 2024, with responsibility for sales, marketing and commercial access, taking over from Schwichtenberg. Ms. Pietryga joins Assertio from Teva Pharmaceuticals, where she was Vice President and Head of the Global Biosimilar Portfolio. In her role, she led a redesign of the global asset portfolio and created a multi-year framework to increase revenue and drive new partnerships. She has also served as Chief Commercial Officer at Peregrine Market Access, leading contract teams delivering end-to-end, fully integrated, CRO and commercial solutions. Previously she was Vice President of Global Marketing at Pacira Biosciences, driving portfolio growth performance through demand generation. She has held leadership and commercial roles in specialty medicines and other categories at Ferring Pharmaceutical, Collegium, Sanofi, Janssen Ortho-McNeil and Merck & Co. She holds a Bachelor of Arts from Michigan State University and a Master of Business Administration from Villanova University. Recent Insider Transactions • Nov 20
Independent Chairman recently bought US$60k worth of stock On the 18th of November, Heather Mason bought around 75k shares on-market at roughly US$0.80 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Heather has been a buyer over the last 12 months, purchasing a net total of US$84k worth in shares. New Risk • Nov 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (US$92.9m market cap). Reported Earnings • Nov 12
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Third quarter 2024 results: US$0.031 loss per share (improved from US$3.42 loss in 3Q 2023). Revenue: US$29.2m (down 18% from 3Q 2023). Net loss: US$2.92m (loss narrowed 99% from 3Q 2023). Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 35%. Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance. Annonce • Nov 12
Assertio Holdings, Inc. Announces Board Changes Assertio Holdings, Inc., on November 11, 2024, announced board changes. Peter Staple retired from the board after more than 20 years as an independent director. Also, Dr. Jeffrey Vacirca has elected to depart from the board to focus on his other business interests. Both departures were effective November 7, 2024. Assertio announced the appointment of Heather Mason as Board Chair. Mason has served as an independent director since 2019 and as interim CEO of Assertio from January to May of 2024. Further, David Stark was appointed to the board as an independent director and member of the Nominating and Corporate Governance Committee. Stark was previously Executive Vice President and Chief Legal Officer at Teva Pharmaceutical Industries Limited. Annonce • Oct 30
Assertio Holdings, Inc. to Report Q3, 2024 Results on Nov 11, 2024 Assertio Holdings, Inc. announced that they will report Q3, 2024 results After-Market on Nov 11, 2024 New Risk • Oct 25
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$94.6m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Market cap is less than US$100m (US$94.6m market cap). Major Estimate Revision • Aug 14
Consensus EPS estimates fall by 20% The consensus outlook for fiscal year 2024 has been updated. 2024 expected loss increased from -US$0.15 to -US$0.18 per share. Revenue forecast unchanged at US$121.7m. Pharmaceuticals industry in the US expected to see average net income decline 3.8% next year. Consensus price target of US$3.15 unchanged from last update. Share price fell 11% to US$1.11 over the past week. New Risk • Aug 08
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$345m Forecast net loss in 1 year: US$4.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$4.8m net loss next year). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Reported Earnings • Aug 08
Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Second quarter 2024 results: US$0.039 loss per share (down from US$0.15 profit in 2Q 2023). Revenue: US$31.1m (down 24% from 2Q 2023). Net loss: US$3.67m (down 143% from profit in 2Q 2023). Revenue exceeded analyst estimates by 3.5%. Earnings per share (EPS) missed analyst estimates by 25%. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance. Annonce • Jul 25
Assertio Holdings, Inc. to Report Q2, 2024 Results on Aug 07, 2024 Assertio Holdings, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024 Annonce • Jul 24
Buxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings On July 24, 2024, The Buxton Helmsley Group Inc announced that it has sent a letter to Board of Directors of Assertio Holdings Inc, stating that it has grave concerns that the current composition of the Company’s Board of Directors is inadequate to meet either the specific requirements of Company’s circumstances or the standard responsibilities of a public Company’s board, called for the immediate resignation of Peter Staple, Heather Mason, William McKee and Jeffrey Vacirca, and intended to nominate Independent, Qualified Directors at the Company’s next shareholder meeting if no progress is made. In addition, Buxton Helmsley Group criticized board’s failure to explain and recover damages from value-destructive spectrum pharmaceuticals acquisition and urged board to improve its due diligence process before any further M&A. Annonce • May 19
The Buxton Helmsley Group Sends Letter to Assertio Holdings On May 18, 2024, The Buxton Helmsley Group Inc announced that issued a letter to Assertio Holdings Inc from Rumbi B Petrozzello, a Certified Public Accountant and Certified Fraud Examiner, stated that in its letter it has provided information about Company’s shareholders and expresses several significant concerns, recommended that further investigation is warranted, but that it should only be conducted by parties not connected to or selected by Assertio's Board and management. In addition, The Buxton Helmsley Group stated that it has released the letter in conjunction with its campaign to urge the Company stockholders to vote against all the Company board nominees at the 2024 annual meeting of shareholders scheduled to be held on May 23, 2024. Annonce • May 08
Assertio Holdings, Inc. Reiterates Earnings Guidance for the Year 2024 Assertio Holdings, Inc. reiterated earnings guidance for the full year 2024. For the year, the company expects net product sales to be in the range of $110.0 Million to $125.0 Million. Reported Earnings • May 07
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2024 results: US$0.047 loss per share. Revenue: US$32.4m (down 24% from 1Q 2023). Net loss: US$4.51m (loss widened 29% from 1Q 2023). Revenue exceeded analyst estimates by 9.9%. Earnings per share (EPS) missed analyst estimates by 67%. Revenue is expected to decline by 4.5% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 9.3%. Annonce • Apr 27
Assertio Holdings, Inc. to Report Q1, 2024 Results on May 06, 2024 Assertio Holdings, Inc. announced that they will report Q1, 2024 results After-Market on May 06, 2024 Annonce • Apr 16
Assertio Holdings, Inc., Annual General Meeting, May 23, 2024 Assertio Holdings, Inc., Annual General Meeting, May 23, 2024, at 12:30 Central Standard Time. Agenda: To elect the six directors named in the Proxy Statement to hold office until the 2025 Annual Meeting of Stockholders and until their successors are duly elected and qualified; to approve an amendment and restatement of the Company's Amended and Restated 2014 Omnibus Incentive Plan, including to increase the number of shares available for issuance thereunder; to approve, on an advisory basis, the compensation of the Company's named executive officers; to approve an amendment to the Company's Certificate of Incorporation to reflect recently adopted Delaware law provisions regarding officer exculpation; and to transact such other business matters. Major Estimate Revision • Mar 18
Consensus revenue estimates fall by 27% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from US$160.6m to US$117.4m. Forecast loss of -US$0.12, down from profit of US$0.16 per share profit previously. Pharmaceuticals industry in the US expected to see average net income growth of 3.1% next year. Consensus price target down from US$3.50 to US$3.00. Share price rose 20% to US$1.12 over the past week. Reported Earnings • Mar 12
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: US$4.67 loss per share (down from US$2.33 profit in FY 2022). Revenue: US$152.1m (down 2.7% from FY 2022). Net loss: US$331.9m (down 403% from profit in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 37%. Revenue is expected to decline by 8.3% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in the US are expected to grow by 8.9%. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings. Annonce • Mar 01
Assertio Holdings, Inc. to Report Q4, 2023 Results on Mar 11, 2024 Assertio Holdings, Inc. announced that they will report Q4, 2023 results After-Market on Mar 11, 2024 New Risk • Feb 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Shareholders have been substantially diluted in the past year (96% increase in shares outstanding). Minor Risk Market cap is less than US$100m (US$75.5m market cap). Annonce • Jan 27
Assertio Holdings, Inc. Announces the Resignation of Daniel A. Peisert as Member of the Board of Directors Assertio Holdings, Inc. announced that on January 24, 2024, Daniel A. Peisert, former President and Chief Executive Officer of the company, executed a waiver and release agreement (Waiver and Release Agreement) substantially in the form included with the Management Continuity Agreement between Mr. Peisert and the Company. Pursuant to and in connection with his execution of the Waiver and Release Agreement, Mr. Peisert resigned as a member of the Board of Directors of the Company, effective immediately. Annonce • Jan 09
Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Assertio Holdings, Inc Bragar Eagel & Squire, P.C. announced that a class action lawsuit has been filed against Assertio Holdings, Inc. (Assertio or the Company) in the United States District Court for the Northern District of Illinois on behalf of all persons and entities who purchased or otherwise acquired Assertio securities between March 9, 2023 and November 8, 2023, both dates inclusive (the Class Period). Investors have until March 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. In July 2023, Assertio acquired Spectrum Pharmaceuticals, Inc. (Spectrum) along with Spectrum's injection asset Rolvedon (the Spectrum Acquisition). According to the complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company's reliance on Indocin products to boost its net income was unsustainable given the risk of generic competition; (ii) the Spectrum Acquisition was less valuable than Assertio had represented to investors; (iii) accordingly, Assertio had overstated the positive impact the sale of Indocin products and the Spectrum Acquisition were likely to have on the Company's profitability; and (iv) as a result, Defendants' public statements were materially false and/or misleading at all relevant times. the complaint alleges that, throughout the Class Period, Defendants' wrongful acts and omissions, and the precipitous decline in the market value of the Company's securities, Plaintiff and other Class members have suffered significant losses and damages. Annonce • Jan 06
Assertio Holdings, Inc. Announces Executive Changes Assertio Holdings, Inc. announced that effective as of January 2, 2024, Daniel A. Peisert, President and Chief Executive Officer and a director of the company separated from service as President and Chief Executive Officer of the company. Effective upon Mr. Peisert’s separation, the Board of Directors of the Company (the “Board”) appointed Heather L. Mason, currently a member of the Board, to serve as the Company’s Interim Chief Executive Officer, to serve while the Board conducts a search for a permanent Chief Executive Officer. Effective upon Ms. Mason’s appointment as Interim Chief Executive Officer, the Board appointed Peter D. Staple as a member of the Audit Committee, appointed Sravan K. Emany as a member of the Compensation Committee and appointed William T. McKee to serve as Chair of the Nominating and Corporate Governance Committee to replace Ms. Mason, who ceased serving on these committees at such time. Annonce • Nov 15
Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors Assertio Holdings, Inc. announced that Sravan Emany has been appointed to the Company's Board of Directors. As part of the appointment, Assertio has expanded its board to seven seats. Mr. Emany currently serves as the Chief Financial Officer of Ironwood Pharmaceuticals. Since December 2021, Mr. Emany has served as Senior Vice President and Chief Financial Officer of Ironwood Pharmaceuticals, a Nasdaq listed healthcare company. Prior to joining Ironwood, Mr. Emany served as Corporate Vice President, Commercial Excellence and Chief Strategy Officer of Integra LifeSciences Holdings Corporation, a publicly traded global healthcare company, from March 2020 until December 2021 and as Vice President of Strategy, Treasury andInvestor Relations from February 2018 to March 2020. Prior to Integra, Mr. Emany served in various mergers and acquisitions investment banking roles at Bank of America and BofA Securities (formerly Bank of America Merrill Lynch) from September 2008 to February 2018, culminating in his service as managing director in the mergers and acquisitions group where he led numerous mergers and acquisitions in the healthcare sector. Mr. Emany also served in various other financial roles, including with Goldman Sachs Group and Morgan Stanley.Mr. Emany holds a B.A. in international relations from The Johns Hopkins University and an M.A. in international relations and international economics from The Johns Hopkins School of Advanced International Studies. New Risk • Nov 14
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: US$98.5m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (96% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Significant insider selling over the past 3 months (US$1.1m sold). Market cap is less than US$100m (US$98.5m market cap). 
